PD-1 inhibitor-Second Affiliated Hospital of Soochow University-solid tumor (advanced)

This record denotes an **unspecified PD-1 inhibitor** used as the immune-checkpoint-blockade component of the Phase II PRaG2.0 rechallenge regimen sponsored by the Second Affiliated Hospital of Soochow University for patients with advanced solid tumors resistant to prior PD-1 or PD-L1 inhibitor therapy. The specific active ingredient, product, manufacturer, and dosage form were not disclosed in the available trial information; therefore, this is not attributable to a unique marketed or investigational PD-1 inhibitor. PD-1 inhibitors block programmed cell death protein 1 signaling, relieving PD-1-mediated suppression of antitumor T-cell activity. In PRaG2.0, the PD-1 inhibitor is administered with hypofractionated radiotherapy, GM-CSF, and IL-2 as separate therapeutic interventions. ([inclinicaltrials.com](https://inclinicaltrials.com/metastatic-solid-tumor/NCT05530200/))

Other names

anti-PD-1 inhibitoranti-PD1 inhibitoranti-PD 1 inhibitorPD-1 checkpoint inhibitorPD1 checkpoint inhibitorPD 1 checkpoint inhibitorPD-1 inhibitorPD1 inhibitorPD 1 inhibitorprogrammed cell death protein 1 inhibitor